Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2, Multi-Center, Randomized Study to Assess Safety, Pharmacokinetics, Immunogenicity, and Efficacy of BAT2020 in Hospitalized Patients Infected With SARS-CoV-2 (COVID-19)

Next Previous
Trial Profile

A Phase 1/2, Multi-Center, Randomized Study to Assess Safety, Pharmacokinetics, Immunogenicity, and Efficacy of BAT2020 in Hospitalized Patients Infected With SARS-CoV-2 (COVID-19)

Status: Withdrawn prior to enrolment
Phase of Trial: Phase I/II

Latest Information Update: 18 Aug 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs BAT 2020 (Primary)
  • Indications COVID 2019 infections
  • Focus Adverse reactions
  • Sponsors Bio-Thera Solutions

Most Recent Events

  • 06 Aug 2021 Status changed from not yet recruiting to withdrawn prior to enrolment.
  • 26 Sep 2020 Phase is changed from phase 1 to phase 1/2 and treatments section is updated to remove specific doses of the drug and instead name the arms as low dose, medium dose and high dose arms. 2 primary end points and all the secondary end-points have been removed.
  • 26 Sep 2020 Planned End Date changed from 18 Jan 2021 to 18 Aug 2021.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top